SCHEMBL17868056

SCHEMBL17868056

Nc1cc(Cl)ccc1-c1ccc(F)cc1F

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.48
TSHR P16473 3/20 0.45
CYP3A4 P08684 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
ALOX15 P16050 3/20 0.45
TDP1 Q9NUW8 1/20 0.45
TP53 P04637 2/20 0.43
HPGD P15428 1/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GRM5 P41594 1/20 0.39
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
TAS1R2 Q8TE23 1/20 0.39
CNR1 P21554 2/20 0.38
KDM4E B2RXH2 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27185985 0.81 ALDH1A1 (0.65) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL30839752 0.81 ALDH1A1 (0.65) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL30839712 0.81 ALDH1A1 (0.65) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL16121126 0.81 HSD11B1 (0.50) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL21638095 0.78 CA3 (0.50) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL4148009 0.78 SMN1; SMN2 (0.46) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL3767151 0.77 ALDH1A1 (0.50) ALDH1A1TSHRCYP3A4SMN1; SMN2ALOX15
SCHEMBL23638850 0.76 S100A4 (0.46) TP53GRM2
SCHEMBL30598347 0.76 S100A4 (0.46) TP53GRM2
SCHEMBL29462674 0.76 ALDH1A1 (0.55) ALDH1A1GRM5KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9708340-B2 Urea derivatives and their use as fatty-acid binding protein (FABP) inhibitors HOFFMANN-LA ROCHE INC. (US) 2017-07-18 US disclosed
US-20160185795-A1 UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS HOFFMANN-LA ROCHE INC. (US) 2016-06-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160185795-A1 UREA DERIVATIVES AND THEIR USE AS FATTY-ACID BINDING PROTEIN (FABP) INHIBITORS FABP1, FABP5, FABP2 ALDH1A1 689/4885TSHR 1871/4885CYP3A4 1971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.